HIV infected individuals show an increased pre-disposition to mycobacterial infection early (M. tuberculosis) and late (M. avium) in their course of disease. In vitro studies suggest that macrophage handling of mycobacteria is not impaired even in the presence of replicating HIV. It is likely that CD4+ cells play the pivotal role in the immune response perhaps in concert with gamma delta T cells which are known to proliferate in response to M. tuberculosis in vitro. It is possible that gamma delta T cells play a role in the immune response to M. avium, and that this infection is not manifest until late in disease when CD4+ cell function is not capable alone of controlling infection. The purpose of our proposal is to identify those defects in the T cell function in response to mycobacterial antigens by, 1) enumerating gamma delta T cells early and late in HIV infection, 2) comparing qualitative and quantitative T cell (CD4+ and gamma delta) responses with cells from subjects who are either tuberculin reactors, or who have a positive history of tuberculin reactivity early and late in HIV infection using in vitro systems of M. tuberculosis infected macrophages, 3) applying in vitro assays of M. avium infected macrophages in patients in early and late HIV infection, 4) studying the effect of therapeutic strategies on T cell responses to M. avium in infected individuals. The goal of our research is to characterize T cell defects which contribute to the pre-disposition to mycobacterial disease in HIV infected individuals. Insights into specific T cell dysfunction may assist in identifying individuals at risk for mycobacterial disease, developing immunomodulatory therapies, and assessing immunologic response to therapy.

Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Beliakova-Bethell, Nadejda; Hezareh, Marjan; Wong, Joseph K et al. (2017) Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. Virology 508:127-133
Osorio, Georgina; Hoenigl, Martin; Quartarolo, Jennifer et al. (2017) Evaluation of opt-out inpatient HIV screening at an urban teaching hospital. AIDS Care 29:1014-1018
Dan, Jennifer M; Massanella, Marta; Smith, Davey M et al. (2016) Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART. J Acquir Immune Defic Syndr 72:133-7
Innes, Steve; Abdullah, Kameelah L; Haubrich, Richard et al. (2016) High Prevalence of Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on Antiretroviral Therapy. Pediatr Infect Dis J 35:e1-7
Vanpouille, Christophe; Introini, Andrea; Morris, Sheldon R et al. (2016) Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection. AIDS 30:193-201
Gianella, Sara; Ginocchio, Christine C; Daar, Eric S et al. (2016) Genital Epstein Barr Virus is associated with higher prevalence and persistence of anal human papillomavirus in HIV-infected men on antiretroviral therapy. BMC Infect Dis 16:24
Massanella, Marta; Gianella, Sara; Schrier, Rachel et al. (2015) Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy. Sci Rep 5:13179
Gianella, Sara; Smith, Davey M; Daar, Eric S et al. (2015) Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with Men. PLoS One 10:e0130410
Blumenthal, Jill; Jain, Sonia; Krakower, Douglas et al. (2015) Knowledge is Power! Increased Provider Knowledge Scores Regarding Pre-exposure Prophylaxis (PrEP) are Associated with Higher Rates of PrEP Prescription and Future Intent to Prescribe PrEP. AIDS Behav 19:802-10
Krishnan, Supriya; Schouten, Jeffrey T; Atkinson, Benjamin et al. (2015) Changes in metabolic syndrome status after initiation of antiretroviral therapy. J Acquir Immune Defic Syndr 68:73-80

Showing the most recent 10 out of 318 publications